|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MED9 |
Gene summary for MED9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MED9 | Gene ID | 55090 |
| Gene name | mediator complex subunit 9 | |
| Gene Alias | MED25 | |
| Cytomap | 17p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NWA0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55090 | MED9 | LZE4T | Human | Esophagus | ESCC | 1.26e-05 | 1.82e-01 | 0.0811 |
| 55090 | MED9 | LZE7T | Human | Esophagus | ESCC | 8.41e-09 | 4.61e-01 | 0.0667 |
| 55090 | MED9 | LZE24T | Human | Esophagus | ESCC | 3.58e-13 | 1.95e-01 | 0.0596 |
| 55090 | MED9 | P1T-E | Human | Esophagus | ESCC | 8.31e-10 | 3.51e-01 | 0.0875 |
| 55090 | MED9 | P2T-E | Human | Esophagus | ESCC | 4.13e-19 | 2.91e-01 | 0.1177 |
| 55090 | MED9 | P4T-E | Human | Esophagus | ESCC | 2.86e-11 | 2.42e-01 | 0.1323 |
| 55090 | MED9 | P5T-E | Human | Esophagus | ESCC | 6.21e-11 | 1.51e-01 | 0.1327 |
| 55090 | MED9 | P8T-E | Human | Esophagus | ESCC | 1.50e-10 | 1.72e-01 | 0.0889 |
| 55090 | MED9 | P10T-E | Human | Esophagus | ESCC | 9.25e-17 | 1.73e-01 | 0.116 |
| 55090 | MED9 | P11T-E | Human | Esophagus | ESCC | 2.91e-08 | 2.78e-01 | 0.1426 |
| 55090 | MED9 | P12T-E | Human | Esophagus | ESCC | 8.28e-26 | 3.01e-01 | 0.1122 |
| 55090 | MED9 | P15T-E | Human | Esophagus | ESCC | 3.06e-07 | 1.33e-01 | 0.1149 |
| 55090 | MED9 | P16T-E | Human | Esophagus | ESCC | 1.42e-24 | 5.08e-01 | 0.1153 |
| 55090 | MED9 | P19T-E | Human | Esophagus | ESCC | 4.69e-02 | 2.52e-01 | 0.1662 |
| 55090 | MED9 | P20T-E | Human | Esophagus | ESCC | 1.83e-06 | 1.66e-01 | 0.1124 |
| 55090 | MED9 | P21T-E | Human | Esophagus | ESCC | 1.09e-07 | 1.48e-01 | 0.1617 |
| 55090 | MED9 | P22T-E | Human | Esophagus | ESCC | 5.80e-20 | 3.69e-01 | 0.1236 |
| 55090 | MED9 | P23T-E | Human | Esophagus | ESCC | 4.87e-07 | 2.26e-01 | 0.108 |
| 55090 | MED9 | P24T-E | Human | Esophagus | ESCC | 2.70e-09 | 1.58e-01 | 0.1287 |
| 55090 | MED9 | P26T-E | Human | Esophagus | ESCC | 2.46e-16 | 2.90e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00069009 | Breast | Precancer | vesicle budding from membrane | 12/1080 | 61/18723 | 1.61e-04 | 2.69e-03 | 12 |
| GO:00481992 | Breast | Precancer | vesicle targeting, to, from or within Golgi | 5/1080 | 21/18723 | 5.93e-03 | 4.21e-02 | 5 |
| GO:000690014 | Breast | IDC | vesicle budding from membrane | 12/1434 | 61/18723 | 2.01e-03 | 1.90e-02 | 12 |
| GO:000690022 | Breast | DCIS | vesicle budding from membrane | 12/1390 | 61/18723 | 1.54e-03 | 1.54e-02 | 12 |
| GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
| GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
| GO:0006900 | Colorectum | AD | vesicle budding from membrane | 32/3918 | 61/18723 | 5.38e-08 | 2.81e-06 | 32 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| GO:0051650 | Colorectum | AD | establishment of vesicle localization | 57/3918 | 161/18723 | 1.47e-05 | 3.15e-04 | 57 |
| GO:0051648 | Colorectum | AD | vesicle localization | 59/3918 | 177/18723 | 7.83e-05 | 1.25e-03 | 59 |
| GO:0006888 | Colorectum | AD | endoplasmic reticulum to Golgi vesicle-mediated transport | 44/3918 | 130/18723 | 4.13e-04 | 4.68e-03 | 44 |
| GO:0006903 | Colorectum | AD | vesicle targeting | 19/3918 | 45/18723 | 9.94e-04 | 9.28e-03 | 19 |
| GO:0048194 | Colorectum | AD | Golgi vesicle budding | 7/3918 | 10/18723 | 1.15e-03 | 1.04e-02 | 7 |
| GO:0006901 | Colorectum | AD | vesicle coating | 9/3918 | 17/18723 | 3.57e-03 | 2.57e-02 | 9 |
| GO:00516561 | Colorectum | SER | establishment of organelle localization | 100/2897 | 390/18723 | 1.11e-07 | 6.79e-06 | 100 |
| GO:00481931 | Colorectum | SER | Golgi vesicle transport | 79/2897 | 296/18723 | 4.20e-07 | 2.15e-05 | 79 |
| GO:00069001 | Colorectum | SER | vesicle budding from membrane | 23/2897 | 61/18723 | 1.95e-05 | 5.66e-04 | 23 |
| GO:00516501 | Colorectum | SER | establishment of vesicle localization | 42/2897 | 161/18723 | 3.38e-04 | 5.35e-03 | 42 |
| GO:00160501 | Colorectum | SER | vesicle organization | 69/2897 | 300/18723 | 3.59e-04 | 5.61e-03 | 69 |
| GO:00068881 | Colorectum | SER | endoplasmic reticulum to Golgi vesicle-mediated transport | 34/2897 | 130/18723 | 1.13e-03 | 1.29e-02 | 34 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MED9 | SNV | Missense_Mutation | novel | c.419N>A | p.Met140Lys | p.M140K | Q9NWA0 | protein_coding | deleterious(0.03) | possibly_damaging(0.478) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MED9 | SNV | Missense_Mutation | c.124C>G | p.Gln42Glu | p.Q42E | Q9NWA0 | protein_coding | tolerated_low_confidence(0.78) | benign(0.015) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| MED9 | SNV | Missense_Mutation | c.424N>A | p.Glu142Lys | p.E142K | Q9NWA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.771) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MED9 | SNV | Missense_Mutation | novel | c.221N>C | p.Lys74Thr | p.K74T | Q9NWA0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MED9 | SNV | Missense_Mutation | novel | c.256N>A | p.Asp86Asn | p.D86N | Q9NWA0 | protein_coding | deleterious(0.04) | benign(0.38) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MED9 | SNV | Missense_Mutation | c.334N>A | p.Glu112Lys | p.E112K | Q9NWA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.454) | TCGA-AX-A06H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
| MED9 | SNV | Missense_Mutation | novel | c.304N>G | p.Ser102Gly | p.S102G | Q9NWA0 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MED9 | SNV | Missense_Mutation | rs137951481 | c.350N>T | p.Gln117Leu | p.Q117L | Q9NWA0 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MED9 | SNV | Missense_Mutation | c.293N>A | p.Arg98His | p.R98H | Q9NWA0 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | |
| MED9 | SNV | Missense_Mutation | novel | c.215N>A | p.Ile72Asn | p.I72N | Q9NWA0 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |